| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | S-8 |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 16 Oct 2026 |
Form 4: Kelly Thomas Patrick, Chief Financial Officer
Received 7,500 shares by exercise or conversion |
| 01 Oct 2026 |
Form 4: Kelly Thomas Patrick, Chief Financial Officer
Bought 15,000 shares ($560K) |
| 01 Oct 2026 |
Form 4: Mortimer Ian, Director
Bought 30,000 shares ($1.12M) |
| 03 Sep 2026 |
Form 4: Svoronos Dawn, Director
Received 5,144 shares by exercise or conversion ($41.9K) |
| 31 Aug 2026 |
Form 4: Kenney Christopher John, Chief Medical Officer
Sold 7,068 shares ($426K) |
| 28 Aug 2026 | 144 |
| 13 Aug 2026 |
Form 4: Gannon Steven, Director
Sold 10,000 shares ($641K) |
| 13 Aug 2026 | 144 |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA |
| 06 Aug 2026 | SCHEDULE 13G/A |
Loading...